Compares two eye implants for diabetic swelling of the retina that resists treatment
Compares fluocinolone and dexamethasone implants in adults with resistant diabetic macular edema.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Dijon
- Where
- Créteil, Dijon, La Tronche, Lyon Cedex 03, Lyon Cedex 04, Marseille, Montauban, Nantes, Nice, Paris Cedex 10, Poitiers, and Vandoeuvre Les Nancy, FranceSee the 12 sites
- Registry title
- Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 106 people, planned
- Started
- 29 Oct 2021
- Expected to end
- 28 Apr 2030
- Type of study
- Interventional
- Record updated
- 30 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetic macular oedema (fluid swelling in the centre of the retina) that has not improved after at least 2 years of treatment, who have already had a lens replacement operation.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Swelling in the centre of the retina thicker than 300 microns that is still present after at least 2 years of treatment and is causing loss of vision. Vision of 80 letters ETDRS or less. If both eyes are affected, the more affected eye is included.
- Earlier treatment
- At least one dexamethasone implant injection that worked for more than 4 months. An anti-VEGF injection more than 3 months ago. Lens replacement surgery more than 6 months ago.
Main reasons for not taking part
- Uveitis, glaucoma or an eye infection
- Glycated haemoglobin above 12% (108 mmol/mol)
- Fluocinolone acetonide (Iluvien) injection in the studied eye less than 24 months ago
- Untreated severe diabetic retinopathy in the studied eye
- Pregnant or breast-feeding women
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Patients who have given their free, informed and written consent
- Patients aged 18 and over
- Patient with DME greater than 300 microns central foveolar thickness still present after at least 2 years of treatment and responsible for a drop in visual activity
- Patient who has had at least one anatomically and functionally effective DXM injection for more than 4 months
- Patient who has had an anti-VEGF injection for more than 3 months
- Pseudophakic patient with surgery more than 6 months ago
- Patients with uni- or bilateral diabetic macular oedema (in the case of bilateral diabetic macular oedema, the most affected eye will be included in the study)
- Best Corrected Visual acuity (BCVA) ≤ 80 letters ETDRS
Who cannot take part
- In the eye studied : - Patient who received an injection of Iluvien (fluocinolone acetonide) less than 24 months ago
- In the eye studied : Patients with ocular hypertonia > 21 mmHg despite treatment with more than 2 molecules
- Patients with a known hypersensitivity to the active substance or to one of the excipients of Ozurdex® or Iluvien®
- Patients with pre-existing uveitis or glaucoma or active or suspected ocular or periocular infection, including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and mycoses
- In the eye studied : Aphakic patients or patients with a history of capsular rupture and wearing an iris-fixed or transcleral implant
- Glycated haemoglobin > 12%
- Person who is not affiliated with the national health insurance system
- Patient unable to give consent
- Patients who have already participated in the study
- Patient for whom the follow-up required by the protocol is not feasible (moving house, etc.)
- In the eye studied : Patients with untreated severe proliferative or non-proliferative diabetic retinopathy
- In the eye studied : Patients who have undergone pan-retinal photocoagulation or focal treatment within the last 3 months
- In the eye studied : Patients with capillary macroaneurysms accessible to focal laser treatment
- In the eye studied : Phakic patients
- Person subject to a measure of legal protection or a court order
- Pregnant, parturient or breast-feeding women
This trial is currently available in France.
- Centre Hospitalier Intercommunal CréteilCréteil, FranceTaking people
- Centre Hospitalier Universitaire de DijonDijon, FranceTaking people
- Centre Hospitalier Universitaire Grenoble AlpesLa Tronche, FranceTaking people
- Hospices Civils De LyonLyon Cedex 03, FranceTaking people
- Hospices Civils De LyonLyon Cedex 04, FranceTaking people
- Centre Monticelli Paradis d'OphtalmologieMarseille, FranceTaking people
- Clinique Honoré CaveMontauban, FranceTaking people
- Centre Hospitalier Universitaire de NantesNantes, FranceTaking people
- Centre Hospitalier Universitaire de NiceNice, FranceTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 10, FranceTaking people
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranceTaking people
- CHRU De NancyVandoeuvre Les Nancy, FranceTaking people
About the trial
What the trial wants to find out
To assess the cost-utility ratio at 3 years of treatment with fluocinolone acetonide (FA) intravitreal implant compared with treatment with dexamethasone (DXM) intravitreal implant in the treatment of resistant DME in pseudophakic patients, from a societal point of view
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- EMMA - Medico Economic Evaluation of Fluocinolone Acetonide Implant Versus Dexametheasone Implant in Resistant Diabetic Macular Oedema
- Plain-language title
- Compares two eye implants for diabetic swelling of the retina that resists treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 30 April 2025